Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ. Sclafani F, et al. Among authors: tabernero j. Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681944 Free article. Clinical Trial.
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Twelves CJ, et al. Among authors: tabernero jm. Clin Colorectal Cancer. 2005 Jul;5(2):101-7. doi: 10.3816/ccc.2005.n.021. Clin Colorectal Cancer. 2005. PMID: 16098250
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J. Paz-Ares L, et al. Among authors: tabernero j. Clin Colorectal Cancer. 2007 May;6(7):522-8. doi: 10.3816/CCC.2007.n.018. Clin Colorectal Cancer. 2007. PMID: 17553201 Clinical Trial.
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J, Van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A. Tabernero J, et al. J Clin Oncol. 2007 Nov 20;25(33):5225-32. doi: 10.1200/JCO.2007.13.2183. J Clin Oncol. 2007. PMID: 18024868 Clinical Trial.
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzén F, Twelves C. Haller DG, et al. Among authors: tabernero j. J Clin Oncol. 2008 May 1;26(13):2118-23. doi: 10.1200/JCO.2007.15.2090. J Clin Oncol. 2008. PMID: 18445840
The role of salvage treatment in advanced colorectal cancer.
Capdevila J, Ramos FJ, Macarulla T, Elez E, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Crit Rev Oncol Hematol. 2009 Jul;71(1):53-61. doi: 10.1016/j.critrevonc.2008.09.006. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977669 Review.
815 results